イドルシアをご存知ない方はこちら。
ピヴラッツっていう薬、知ってますか？
まず本決算。
Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company
"Approximately 25% of aSAH patients were treated with PIVLAZ in December 2022, based on the estimated incidence of aSAH in Japan. Since the launch in April, net sales in 2022 reached CHF 44 million."
おお。約60億円。8ヶ月ちょっとで。このまま行けば、毎年この薬のために100億円が使われることになる。
そしてREACTの結果。
Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage
"The study did not meet the primary endpoint."
"The company will publish the data and interpretation in scientific literature in due course."
書いてあるのはこれだけ。
さあ、面白くなってまいりました。
ピヴラッツっていう薬、知ってますか？
まず本決算。
Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company
"Approximately 25% of aSAH patients were treated with PIVLAZ in December 2022, based on the estimated incidence of aSAH in Japan. Since the launch in April, net sales in 2022 reached CHF 44 million."
おお。約60億円。8ヶ月ちょっとで。このまま行けば、毎年この薬のために100億円が使われることになる。
そしてREACTの結果。
Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage
"The study did not meet the primary endpoint."
"The company will publish the data and interpretation in scientific literature in due course."
書いてあるのはこれだけ。
さあ、面白くなってまいりました。
アクセス
